This inventor holds 35 USPTO granted patents and 5 published patent applications, primarily in Cancer Immunotherapy. Top assignees: Immatics Biotechnologies Gmbh, Other. Active years: 2018-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tübingen, DE (2018 - 2019)
- Tuebingen, DE (2018 - 2024)
Company Filing History:
34 out of 728 
1 out of 834,513 Years Active: 2018-2025
Areas of Expertise:
Title: Inventor Spotlight: Helen Hoerzer Revolutionizing Cancer Immunotherapy
Introduction: Helen Hoerzer, a brilliant inventor hailing from Tuebingen, Germany, has made significant strides in the field of cancer immunotherapy. With an impressive portfolio of 34 patents, her groundbreaking work is shaping the future of cancer treatment.
Latest Patents: Helen's latest patents focus on peptides and a combination of peptides for use in immunotherapy against ovarian cancer and various other types of cancers. These patents emphasize the development of immunotherapeutic methods involving peptides, proteins, nucleic acids, and cells to stimulate anti-tumor immune responses. The innovative approach highlights the immunotherapy of cancer through the utilization of tumor-associated T-cell peptide epitopes and other peptides as active pharmaceutical ingredients in vaccine compositions.
Career Highlights: Throughout her illustrious career, Helen Hoerzer has worked with leading companies in the biotechnology sector. Notable mentions include Immatics Biotechnologies GmbH, where she contributed significantly to cutting-edge research and development in the field of immunotherapy. Her innovative mindset and dedication have propelled her to the forefront of the biotech industry, where she continues to make a lasting impact.
Collaborations: Collaborating with esteemed professionals such as Andrea Mahr and Oliver Schoor, Helen Hoerzer has fostered an environment of innovation and scientific excellence. Together, they have spearheaded research projects aimed at advancing cancer immunotherapy and unlocking new possibilities in the fight against cancer. Their collective expertise and collaborative efforts have yielded groundbreaking results in the field.
Conclusion: Helen Hoerzer's relentless pursuit of innovation and her passion for revolutionizing cancer immunotherapy have solidified her position as a trailblazer in the biotechnology landscape. Her inventive spirit and dedication to advancing healthcare technologies underscore her commitment to making a difference in the lives of patients battling cancer. As she continues to push boundaries and explore new frontiers in immunotherapy, Helen Hoerzer remains a driving force for positive change in the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile